Coxsackie B neutralisation titres in polymyositis/dermatomyositis

B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

Clinical and experimental immunology·2017

Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Clinical and experimental immunology·2015

Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.

Clinical and experimental immunology·2014

The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Journal of autoimmunity·2013

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.

Clinical and experimental rheumatology·2008

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Annals of the rheumatic diseases·2007

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Malar rash in systemic lupus erythematosus: clinical, serological, and therapeutic associations in a single-center retrospective study of 1039 patients.

Polish archives of internal medicine·2026

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Acta dermato-venereologica·2026

Neutrophil reactivity intensity correlates with the SOFA score in adults with sepsis: a cross-sectional study from an Indonesian tertiary hospital.

Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina·2026

Idiopathic granulomatous mastitis a mimicking disease: a case report.

AME case reports·2026

A prospective, observational study of efficacy and safety of desloratadine and bilastine in patients of chronic spontaneous urticaria.

Perspectives in clinical research·2026

First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report.

Case reports in rheumatology·2026

Related Experiment Videos

Coxsackie B neutralisation titres in polymyositis/dermatomyositis

Related Concept Videos

B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.

The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Malar rash in systemic lupus erythematosus: clinical, serological, and therapeutic associations in a single-center retrospective study of 1039 patients.

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Neutrophil reactivity intensity correlates with the SOFA score in adults with sepsis: a cross-sectional study from an Indonesian tertiary hospital.

Idiopathic granulomatous mastitis a mimicking disease: a case report.

A prospective, observational study of efficacy and safety of desloratadine and bilastine in patients of chronic spontaneous urticaria.

First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report.

Related Experiment Videos

Coxsackie B neutralisation titres in polymyositis/dermatomyositis

Related Concept Videos

Related Articles